Roivant Sciences vs Zenas BioPharma
ROIV and ZBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ROIV and ZBIO compare
Roivant Sciences is the larger company, worth 14 times as much as Zenas BioPharma ($26.7B against $1.9B).
Roivant Sciences scores higher on the StockData Score (7 against 1 for Zenas BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ROIV | ZBIO |
|---|---|---|
| Size and price | ||
| Market cap | $26.7B | $1.9B |
| Share price | $36.91 | $28.39 |
| Change, 1 year | 96.7% | 1.4% |
| Change, 5 years | 377% | – |
| Beta (5Y) | 0.86 | 0.42 |
| Employees | 721 | 167 |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3540× | – |
| P/B | 6.3× (better) | 7.5× |
| FCF yield | −3.1% (better) | −12.2% |
| Growth | ||
| Revenue growth (TTM) | −67.6% | – |
| Revenue growth, 5Y average | −19.1% | – |
| Profitability | ||
| Operating margin | −7915% | – |
| Net margin | −3535% | – |
| FCF margin | −10901% | – |
| Return on equity | −6.2% (better) | −199% |
| Return on invested capital | −407% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.90 (better) |
| Current ratio | 16.72 (better) | 9.93 |
| Altman Z-score | 41.99 (better) | −0.70 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 78.1% | 94.0% |
| Held by insiders | 14.3% | 36.1% |
| Insider net buying, 12 months | −$870M | $11.4M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 6.3% | 28.7% |
Go deeper
- ROIV stock overview
- ROIV income statement
- ROIV valuation and score
- ZBIO stock overview
- ZBIO income statement
- ZBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.